ProShares Ultra NASDAQ Biotechnology
BIB
BIB
21 hedge funds and large institutions have $5.9M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
44% less call options, than puts
Call options by funds: $849K | Put options by funds: $1.52M
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Holders
21
Holding in Top 10
–
Calls
$849K
Puts
$1.52M
Top Buyers
| 1 | +$260K | |
| 2 | +$184K | |
| 3 | +$66.4K | |
| 4 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$9K |
| 5 |
Morgan Stanley
New York
|
+$2.25K |
Top Sellers
| 1 | -$741K | |
| 2 | -$366K | |
| 3 | -$325K | |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$212K |
| 5 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
-$208K |